An update on the management of Chagas cardiomyopathy

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 4, 2007, Pages 727-743

  Rocha, Manoel O C ^a   Teixeira, Mauro M ^a   Ribeiro, Antonio L ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Arrhythmia; Benznidazole; Carvedilol; Chagas disease; Heart block; Heart failure

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; BENZNIDAZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CARVEDILOL; COUMARIN; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; NIFURTIMOX; PLACEBO; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; WARFARIN;

AGRANULOCYTOSIS; ANOREXIA; ANTIBODY DETECTION; ANTICOAGULATION; BLOOD SAMPLING; BRADYCARDIA; CARDIOMYOPATHY; CELL THERAPY; CEREBROVASCULAR ACCIDENT; CHAGAS DISEASE; CLINICAL TRIAL; COLIC; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; DISEASE TRANSMISSION; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXCITABILITY; EXERCISE TEST; FEVER; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART PACING; HEART RIGHT BUNDLE BRANCH BLOCK; HEART RIGHT VENTRICLE FUNCTION; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LUNG EMBOLISM; LUNG TOXICITY; LYMPHADENOPATHY; MENTAL DISEASE; NAUSEA; NEUTROPENIA; PACEMAKER; PARASITE PREVALENCE; POLYMERASE CHAIN REACTION; PROGNOSIS; RADIOIMMUNOPRECIPITATION; REVIEW; SENSORY NEUROPATHY; SEROLOGY; SIDE EFFECT; SOMNOLENCE; SURVIVAL RATE; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; THROMBOEMBOLISM; THYROID DISEASE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRYPANOSOMA CRUZI; VOMITING; WEIGHT REDUCTION;

EID: 34547855487     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.4.727     Document Type: Review

References (150)

1. Control of Chagas disease. World Health Organ. Tech. Rep. Ser. 905, i-109 (2002).
2. Rocha MO, Ribeiro AL, Teixeira MM. Clinical management of chronic Chagas cardiomyopathy. Front Biosci. 8, e44-e54 (2003).
3. Chagas' disease - an epidemic that can no longer be ignored. Lancet 368(9536), 619 (2006).
4. PAHO. Chagas disease: fact sheet and poster (2007).
5. Wilson LS, Strosberg AM, Barrio K. Cost-effectiveness of Chagas disease interventions in Latin America and the Caribbean: Markov models, Am. J. Trop. Med. Hyg. 73(5), 901-910 (2005).
6. Dias JC. The treatment of Chagas disease (South American trypanosomiasis). Ann. Intern. Med. 144(10), 772-774 (2006).
7. Dias JC. [Notes about of Trypanosoma cruzi and yours bio-ecology characteristics with agents of the transmission by meals]. Rev. Soc. Bras. Med. Trop. 39(4), 370-375 (2006).
8. Chagas disease after organ transplantation - Los Angeles, California, 2006. Morb. Mortal. Wkly Rep. 55(29), 798-800 (2006).
9. Herwaldt BL. Laboratory-acquired parasitic infections from accidental exposures. Clin. Microbiol. Rev. 14(4), 659-88 (2001).
10. Schofield CJ, Jannin J, Salvatella R. The future of Chagas disease control. Trends Parasitol. 22(12), 583-588 (2006).
11. Yamagata Y, Nakagawa J. Control of Chagas disease. Adv. Parasitol. 61, 129-165 (2006).
12. Dias JC. Chagas disease: successes and challenges. Cad. Saude Publica 22(10), 2020-2021 (2006).
13. Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Mem. Inst. Oswaldo Cruz 98(5), 577-591 (2003).
14. Costa Rocha MO, Correia PC, Barros MV, Torres RM, Ribeiro AL, Teixeira MM. Cardiovascular function in elderly patients with chronic chagasic cardiopathy. Rev. Soc. Bras. Med. Trop. 36(5), 545-550 (2003).
15. Lima-Costa MF, Barreto SM, Guerra HL. Chagas' disease among older adults: branches or mainstream of the present burden of Trypanosoma cruzi infection? Int. J. Epidemiol. 31(3), 688-689 (2002).
16. Lima e Costa MF, Barreto SM, Guerra HL, Firmo JO, Uchoa E, Vidigal PG. Ageing with Trypanosoma cruzi infection in a community where the transmission has been interrupted: the Bambui Health and Ageing Study (BHAS). Int. J. Epidemiol. 30(4), 887-893 (2001).
17. Blood donor screening for Chagas disease - United States, 2006-2007. Morb. Mortal. Wkly Rep. 56(7), 141-143 (2007).
18. Garraud O, Andreu G, Elghouzzi MH, Laperche S, Lefrere JJ. Measures to prevent transfusion-associated protozoal infections in non-endemic countries. Travel. Med. Infect. Dis. 5(2), 110-112 (2007).
19. [Brazilian Consensus on Chagas disease]. Rev. Soc. Bras. Med. Trop. 38(Suppl. 3), 7-29 (2005).
20. Ferreira MS, Nishioka SA, Silvestre MT, Borges AS, Nunes-Araujo FR, Rocha A. Reactivation of Chagas' disease in patients with AIDS: report of three new cases and review of the literature. Clin. Infect. Dis. 25(6), 1397-1400 (1997).
21. Sartori AM, Ibrahim KY, Nunes Westphalen EV et al. Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS. Ann. Trop. Med. Parasitol. 101(1), 31-50 (2007).
22. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect. Dis. 1(2), 92-100 (2001).
23. Ribeiro AL, Rocha MO. [Indeterminate form of Chagas disease; considerations about diagnosis and prognosis]. Rev. Soc. Bras. Med. Trop, 31(3), 301-314 (1998).
24. Dias JC. The indeterminate form of human chronic Chagas' disease. A clinical epidemiological review. Rev. Soc. Bras. Med. Trop. 22(3), 147-156 (1989).
25. Barros MV, Rocha MO, Ribeiro AL, Machado FS. Doppler tissue imaging to evaluate early myocardium damage in patients with undetermined form of Chagas' disease and normal echocardiogram, Echocardiography 18(2), 131-136 (2001).
26. Marin-Neto JA, Almeida Filho OC, Pazin-Filho A, Maciel BC. [Indeterminate form of Chagas' disease. Proposal of new diagnostic criteria and perspectives for early treatment of cardiomyopathy]. Arq. Bras. Cardiol. 79(6), 623-627 (2002).
27. Ribeiro AL, Moraes RS, Ribeiro JP et al. Parasympathetic dysautonomia precedes left ventricular systolic dysfunction in Chagas disease. Am. Heart J. 141(2), 260-265(2001).
28. Ribeiro AL, Ferreira LM, Oliveira E, Cruzeiro PC, Torres RM, Rocha MO. Active orthostatic stress and respiratory sinus arrhythmia in patients with Chagas' disease with preserved left ventricular global systolic function. Arq. Bras. Cardiol. 83(1), 40-44 (2004).
29. Pazin-Filho A, Romano MM, Almeida-Filho OC et al. Minor segmental wall motion abnormalities detected in patients with Chagas' disease have adverse prognostic implications. Braz. J. Med. Biol. Res. 39(4), 483-487 (2006).
30. Espinosa R, Carrasco HA, Belandria F et al. Life expectancy analysis in patients with Chagas' disease: prognosis after one decade (1973-1983). Int. J. Cardiol. 8(1), 45-56 (1985).
31. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simoes MV. Pathogenesis of chronic Chagas heart disease. Circulation 115(9), 1109-1123 (2007).
32. + T cells with the presence of Typanosoma cruzi antigens in chronic, human, chagasic myocarditis. Am. J. Trop. Med. Hyg. 56(5), 485-489 (1997).
33. Jones EM, Colley DG, Tostes S, Lopes ER, Vnencak-Jones CL, McCurley TL. Amplification of a Trypanosoma cruzi DNA sequence from inflammatory lesions in human chagasic cardiomyopathy. Am. J. Trop. Med. Hyg. 48(3), 348-357 (1993).
34. Tarleton RL. Parasite persistence in the aetiology of Chagas disease. Int. J. Parasitol. 31(5-6), 550-554 (2001).
35. Soares MB, Ponres-de-Carvalho L, Ribeiro-dos-Santos R. The pathogenesis of Chagas' disease: when autoimmune and parasite-specific immune responses meet. An. Acad. Bras. Cienc. 73(4), 547-559 (2001).
36. Teixeira VP, Araujo MB, Dos Reis MA et al. Possible role of an adrenal parasite reservoir in the pathogenesis of chronic Trypanosoma cruzi myocarditis. Trans. R. Soc. Trop. Med. Hyg. 87(5), 552-554 (1993).
37. Miles MA, Cedillos RA, Povoa MM, de Souza AA, Prata A, Macedo V. Do radically dissimilar Typanosoma cruzi strains (zymodemes) cause Venezuelan and Brazilian forms of Chagas' disease? Lancet 1(8234), 1338-1340 (1981).
38. Rossi MA, Ramos SG, Bestetti RB. Chagas' heart disease: clinical-pathological correlation. Front Biosci. 8, e94-e109 (2003).
39. Bogliolo L. [Anatomic causes of cardiac insufficiency in chronic chagasic cardiopathy (myocarditis) studied in comparison to anatomic causes of cardiac insufficiency in other cardiopathies. Part I]. Arq. Bras. Cardiol. 29, 419-424 (1976).
40. Bogliolo L. [Anatomic causes of cardiac insufficiency in chronic chagasic cardiopathy (myocarditis) studied in comparison to anatomic causes of cardiac insufficiency in other cardiopathies. Part II]. Arq. Bras. Cardiol. 29, 479-483 (1976).
41. Rassi A Jr., Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation 115(9), 1101-1108 (2007).
42. Carrasco HA, Parada H, Guerrero L, Duque M, Duran D, Molina C. Prognostic implications of clinical, electrocardiographic and hemodynamic findings in chronic Chagas' disease. Int. J. Cardiol. 43(1), 27-38 (1994).
43. Mady C, Cardoso RH, Barretto AC, da Luz PL, Bellotti G, Pileggi F. Survival and predictors of survival in patients with congestive heart failure due to Chagas' cardiomyopathy. Circulation 90(6), 3098-3102 (1994).
44. Salles G, Xavier S, Sousa A, Hasslocher-Moreno A, Cardoso C. Prognostic value of QT interval parameters for mortality risk stratification in Chagas' disease: results of a long-term follow-up study. Circulation 108(3), 305-312 (2003).
45. Viotti R, Vigliano C, Lococo B et al. [Clinical predictors of chronic chagasic myocarditis progression]. Rev. Esp. Cardiol. 58(9), 1037-1044 (2005).
46. Leire LR, Fenelon G, Simoes A Jr, Silva GG, Friedman PA, de Paola AA. Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with arniodarone or sotalol. J. Cardiovasc. Electrophysiol. 14(6), 567-573 (2003).
47. Silva RM, Tavora MZ, Gondim FA, Metha N, Hara VM, Paola AA. Predictive value of clinical and electrophysiological variables in patients with chronic chagasic cardiomyopathy and nonsustained ventricular tachycardia. Arq. Bras. Cardiol. 75(1), 33-47 (2000).
48. Rassi A Jr, Rassi A, Little WC et al. Development and validation of a risk score for predicting death in Chagas' heart disease. N. Engl. J. Med. 355(8), 799-808 (2006).
49. Rocha MO, Ribeiro, AL. A risk score for predicting death in Chagas' heart disease. N. Engl. J. Med. 355(23), 2488-2489 (2006).
50. Leiby DA, Wendel S, Takaoka DT, Fachini RM, Oliveira LC, Tibbals MA. Serologic testing for Trypanosoma cruzi: comparison of radioimmunoprecipitation assay with commercially available indirect immunofluorescence assay, indirect hemagglutination assay, and enzyme-linked immunosorbent assay kits. J. Clin. Microbiol. 38(2), 639-642 (2000).
51. Chiari E, Dias JC, Lana M, Chiari CA. Hemocultures for the parasitological diagnosis of human chronic Chagas' disease. Rev. Soc. Bras. Med. Trop. 22(1), 19-23 (1989).
52. Galvao LM, Cancado JR, Rezende DF, Krettli AU. Hemocultures from chronic Chagasic patients using EDTA or heparin as anticoagulants. Braz. J. Med. Biol. Res. 22(7), 841-843 (1989).
53. Marcon GE, Andrade PD, de Albuquerque DM et al. Use of a nested polymerase chain reaction (N-PCR) to detect Trypanosoma cruzi in blood samples from chronic chagasic patients and patients with doubtful serologies. Diagn. Microbiol. Infect. Dis. 43(1), 39-43 (2002).
54. Portela-Lindoso AA, Shikanai-Yasuda MA. [Chronic Chagas' disease: from xenodiagnosis and hemoculture to polymerase chain reaction]. Rev. Saude Publica 37(1), 107-115 (2003).
55. Maldonado C, Albano S, Vettorazzi L et al. Using polymerase chain reaction in early diagnosis of re-activated Trypanosoma cruzi infection after heart transplantation. J. Heart Lung Transplant. 23(12), 1345-1348 (2004).
56. Schijman AG, Vigliano C, Burgos J et al. Early diagnosis of recurrence of Trypanosoma cruzi infection by polymerase chain reaction after heart transplantation of a chronic Chagas' heart disease patient. J. Heart Lung Transplant. 19(11), 1114-1117 (2000).
57. Bestetti RB, Ariolli MT, do Carmo JL et al. Clinical characteristics of acute myocardial infarction in patients with Chagas' disease. Int. J. Cardiol. 35(3), 371-376 (1992).
58. Barros MV, Machado FS, Ribeiro AL, Costa Rocha MO. Detection of early right ventricular dysfunction in Chagas' disease using Doppler tissue imaging. J. Am. Soc. Echocardiogr. 15 (10 Pt 2), 1197-1201 (2002).
59. Marin-Neto JA, Marzullo P, Sousa AC et al. Radionuclide angiographic evidence for early predominant right ventricular involvement in patients with Chagas' disease. Can. J. Cardiol. 4(5), 231-236 (1988).
60. Nunes MC, Barbosa MM, Brum, VA, Rocha MO. Morphofunctional characteristics of the right ventricle in Chagas' dilated cardiomyopathy. Int. J Cardiol. 94(1), 79-85 (2004).
61. Barros MY, Machado FS, Ribeiro AL, Rocha MO. Diastolic function in Chagas' disease: an echo and tissue Doppler imaging study. Eur. J. Echocardiogr. 5(3), 182-188 (2004).
62. Rassi A Jr, Rassi SG, Rassi A. Sudden death in Chagas' disease. Arq. Bras. Cardiol. 76(1), 75-96 (2001).
63. Martinelli FM, De Siqueira SF, Moreira H et al. Probability of occurrence of life-threatening ventricular arrhythmias in Chagas' disease versus non-Chagas' disease. Pacing Clin. Electrophysiol. 23(11 Pt 2), 1944-1946 (2000).
64. Sternick EB, Martinelli M, Sampaio, R et al. Sudden cardiac death in patients with chagas heart disease and preserved left ventricular function. J. Cardiovasc. Electrophysiol. 17(1), 113-116 (2006).
65. Dias JC, Kloetzel K. The prognostic value of the electrocardiographic features of chronic Chagas' disease. Rev. Inst. Med. Trop. Sao Paulo 10(3), 158-162 (1968).
66. Ribeiro AL, Rocha MO, Barros MV, Rodrigues AR, Machado FS. A narrow QRS does not predict a normal left ventricular function in Chagas' disease. Pacing Clin. Electrophysiol. 23(11 Pt 2), 2014-2017 (2000).
67. Rincon LG, Rocha MO, Pires MT et al. [Clinical profile of Chagas and non-Chagas' disease patients with cardiac pacemaker]. Rev. Soc. Bras. Med Trop. 39(3), 245-249 (2006).
68. Nunes MC, Barbosa MM, Rocha MO. Peculiar aspects of cardiogenic embolism in patients with Chagas' cardiomyopathy: a transthoracic and transesophageal echocardiographic study. J. Am. Soc. Echocardiogr. 18(7), 761-767 (2005).
69. Carod-Artal FJ, Vargas AP, Horan TA, Nunes LG. Chagasic cardiomyopathy is independently associated with ischemic stroke in Chagas disease. Stroke 36(5), 965-970 (2005).
70. Carod-Artal FJ, Vargas AP, Melo M, Horan TA. American trypanosomiasis (Chagas' disease): an unrecognised cause of stroke. J. Neurol. Neurosurg. Psychiatry 74(4), 516-518 (2003).
71. Kuschnir E, Sgammini H, Castro R, Evequoz C, Ledesma R, Brunetto J. [Evaluation of cardiac function by radioisotopic angiography, in patients with chronic Chagas cardiopathy]. Arq. Bras. Cardiol. 45(4), 249-256 (1985).
72. Carrasco HA, Guerrero L, Parada H, Molina C, Vegas E, Chuecos R. Ventricular arrhythmias and left ventricular myocardial function in chronic chagasic patients. Int. J. Cardiol. 28(1), 35-41 (1990).
73. Viotti R, Vigliano C, Lococo B et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann. Intern. Med. 144(10), 724-734 (2006).
74. Benchimol Barbosa PR. Noninvasive prognostic markers for cardiac death and ventricular arrhythmia in long-term follow-up of subjects with chronic Chagas' disease. Braz. J. Med. Biol. Res. 40(2), 167-178 (2007).
75. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112(12), e154-e235 (2005).
76. Bocchi EA, Vilas-Boas F, Perrone S et al. I Latin American guidelines for the assessment and management of decompensated heart failure. Arq. Bras. Cardiol. 85(Suppl. 3), 49-94 (2005).
77. Maguire JH, Hoff R, Sherlock I et al. Cardiac morbidity and mortality due to Chagas' disease: prospective electrocardiographic study of a Brazilian community. Circulation 75(6), 1140-1145 (1987).
78. Barros MV, Costa Rocha MO, Ribeiro AL, Machado FS. Tissue Doppler imaging enables the identification of diastolic dysfunction of pseudonormal pattern in Chagas' disease. J. Am. Soc. Echocardiogr. 14(5), 353-359 (2001).
79. Barros MV Ribeiro AL, Machado FS, Rocha MO. Doppler tissue imaging to assess systolic function in Chagas' disease. Arq. Bras. Cardiol. 80(1), 36-5 (2003).
80. Barros MVL, Rocha MOC, Riberio ALP, Machado FS. Tissue Doppler imaging in the evaluation of the regional diastolic function in Chagas' disease. Eur. J. Echocardiogr. 2(2), 94-99 (2001).
81. Silva CE, Ferreira LD, Peixoto LB et al. [Evaluation of segmentary contractility in Chagas' disease by using the integral of the myocardial velocity gradient (myocardial strain) obtained through tissue Doppler echocardiography]. Arq. Bras. Cardiol. 84(4), 285-291 (2005).
82. Perez AA, Ribeiro AL, Barros MV et al. Value of the radiological study of the thorax for diagnosing left ventricular dysfunction in Chagas' disease. Arq. Bras. Cardiol. 80(2), 208-7 (2003).
83. Barbosa MM, Nunes MD, Ribeiro AL, Barral MM, Rocha MO. N-terminal proBNP levels in patients with Chagas disease: a marker of systolic and diastolic dysfunction of the left ventricle. Eur. J. Echocardiogr. 8(3), 204-212 (2006).
84. Ribeiro AL, dos Reis AM, Barros MV et al. Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease. Lancet 360(9331), 461-462 (2002).
85. Ribeiro AL, Reis AM, Teixeira MM, Rocha MO. Brain natriuretic peptide in Chagas' disease: further insights. Lancet 362(9380), 333 (2003).
86. Ribeiro AL, Teixeira MM, Reis AM et al. Brain natriuretic peptide based strategy to detect left ventricular dysfunction in Chagas disease: a comparison with the conventional approach. Int. J. Cardiol. 109(1), 34-40 (2006).
87. Talvani A, Rocha MO, Cogan J et al. Brain natriuretic peptide and left ventricular dysfunction in chagasic cardiomyopathy. Mem. Inst. Oswaldo Cruz 99(6), 645-649 (2004).
88. Talvani A, Rocha MO, Cogan J et al. Brain natriuretic peptide measurement in Chagas heart disease: marker of ventricular dysfunction and arrhythmia. Int. J. Cardiol. 100(3), 503-504 (2005).
89. Grupi CJ, Moffa PJ, Barbosa SA et al. Holter monitoring in Chagas' heart disease. Sao Paulo Med. J. 113(2), 835-840 (1995).
90. Martinelli FM, Sosa E, Nishioka S, Scanavacca M, Bellotti G, Pileggi F. Clinical and electrophysiologic features of syncope in chronic chagasic heart disease. J. Cardiovasc. Electrophysiol. 5(7), 563-570 (1994).
91. Lombardi F, Malliani A, Pagani M, Cerutri S. Heart rate variability and its sympatho-vagal modulation. Cardiovasc. Res. 32(2), 208-216 (1996).
92. Ribeiro AL, Lombardi F, Sousa MR et al. Power-law behavior of heart rate variability in Chagas' disease. Am. J. Cardiol. 89(4), 414-418 (2002).
93. Ribeiro AL, Lombardi F, Sousa MR, Rocha MO. Vagal dysfunction in Chagas disease. Int. J. Cardiol. 103(2), 225-226 (2005).
94. Ribeiro AL, Schmidt G, Sousa MR et al. Heart rate turbulence in Chagas disease. Pacing Clin. Electrophysiol. 26(1 Pt 2), 406-410 (2003).
95. Tundo F, Lombardi F, Rocha MC et al. Heart rate turbulence and left ventricular ejection fraction in Chagas disease. Europace 7(3), 197-203 (2005).
96. Makikallio TH, Barthel P, Schneider R et al. Prediction of sudden cardiac death after acute myocardial infarction: role of Holter monitoring in the modern treatment era. Eur. Heart J. 26(8), 762-769 (2005).
97. de Paola AA, Gomes JA, Terzian AB, Miyamoto MH, Martinez Fo EE. Ventricular tachycardia during exercise testing as a predictor of sudden death in patients with chronic chagasic cardiomyopathy and ventricular arrhythmias. Br. Heart J. 74(3), 293-295 (1995).
98. Rocha AL, Rocha MO, Teixeira BO et al. [Chronotropic-metabolic index in Chagas' disease]. Rev. Soc. Bras. Med. Trop. 38(5), 373-376 (2005).
99. Rocha AL, Lombardi F, Costa Rocha MO et al. Chronotropic incompetence and abnormal autonomic modulation in ambulatory Chagas disease patients. Ann. Noninvasive Electrocardiol. 11 (1), 3-11 (2006).
100. Marin-Neto JA, Marzullo P, Marcassa C et al. Myocardial perfusion abnormalities in chronic Chagas' disease as detected by thallium-201 scintigraphy. Am. J. Cardiol. 69(8), 780-784 (1992).
101. Simoes MV, Pintya AO, Bromberg-Marin G et al. Relation of regional sympathetic denervation and myocardial perfusion disturbance to wall motion impairment in Chagas' cardiomyopathy. Am. J. Cardiol. 86(9), 975-981 (2000).
102. Simoes MV, Ayres EM, Santos JL et al. [Detection of myocardial ischemia in chronic Chagas disease patients with atypic precordial pain by exercise and Holter tests]. Arq. Bras. Cardiol. 60(5), 315-319 (1993).
103. Rochitte CE, Nacif MS, Oliveira Junior AC et al. Cardiac magnetic resonance in Chagas' disease. Artif. Organs 31(4), 259-267 (2007).
104. Rochitte CE, Oliveira PF, Andrade JM et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas' disease: a marker of disease severity. J. Am. Coll. Cardiol. 46(8), 1553-1558 (2005).
105. Urbina JA. Chemotherapy of Chagas disease. Curr. Pharm. Des. 8(4), 287-295 (2002).
106. Castro JA, de Mecca MM, Bartel LC. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum. Exp. Toxicol. 25(8), 471-479 (2006).
107. Cancado JR. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev. Inst. Med. Trop. Sao Paulo 44(1), 29-37 (2002).
108. de Andrade AL, Zicker F, de Oliveira RM et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348(9039), 1407-1413 (1996).
109. Sosa ES, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C, Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am. J. Trop. Med. Hyg. 59(4), 526-529 (1998).
110. Andrade AL, Martelli CM, Oliveira RM et al. Short report: benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. Am. J. Trop. Med. Hyg. 71(5), 594-597 (2004).
111. Villar JC, Marin-Nero JA, Ebrahim S, Yusuf S. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst. Rev. 1, CD003463 (2002).
112. Reyes PA, Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst. Rev. 4, CD004102 (2005).
113. Teixeira AR, Calixto MA, Teixeira ML. Chagas' disease: carcinogenic activity of the antitrypanosomal nitroarenes in mice. Mutat. Res. 305(2), 189-196 (1994).
114. Andrade SG, Freitas LA, Peyrol S, Pimentel AR, Sadigursky M. Experimental chemotherapy of Trypanosoma cruzi infection: persistence of parasite antigens and positive setology in parasitologically cured mice. Bull. World Health Organ. 69(2), 191-197 (1991).
115. Silva ED, Peteita VR, Gomes JA et al. Use of the EIE-recombinant-Chagas-biomanguinhos kit to monitor cure of human Chagas' disease. J. Clin. Lab. Anal. 16(3), 132-136 (2002).
116. Sanchez G, Coronado X, Zulantay I et al. Monitoring the efficacy of specific treatment in chronic Chagas disease by polymerase chain reaction and flow cytometry analysis. Parasite 12(4), 353-357 (2005).
117. Britto C, Cardoso MA, Vanni CM et al. Polymerase chain reaction detection of Trypanosoma cruzi in human blood samples as a tool for diagnosis and treatment evaluation. Parasitology 110(Pt 3) 241-247 (1995).
118. Gomes ML, Galvao LM, Macedo AM, Pena SD, Chiari E. Chagas' disease diagnosis: comparative analysis of parasitologic, molecular, and serologic methods. Am. J. Trop. Med. Hyg. 60(2), 205-210 (1999).
119. Bestetti RB, Muccillo G. Clinical course of Chagas' heart disease: a comparison with dilated cardiomyopathy. Int. J. Cardiol. 60(2), 187-193 (1997).
120. Freitas HF, Chizzola PR, Paes AT, Lima AC, Mansur AJ. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas' heart disease. Int. J. Cardiol. 102(2), 239-247 (2005).
121. Khoury AM, Davila DF, Bellabarba G et al. Acute effects of digitalis and enalapril on the neurohormonal profile of chagasic patients with severe congestive heart failure. Int. J. Cardiol. 57(1), 21-29 (1996).
122. Roberti RR, Martinez EE, Andrade JL et al. Chagas cardiomyopathy and captopril. Eur. Heart J. 13(7), 966-970 (1992).
123. Botoni FA, Poole-Wilson PA, Ribeiro AL et al. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am. Heart J. 153(4), 544-548 (2007).
124. Davila DF, Angel F, Arata, DB, Donis JH. Effects of metoprolol in chagasic patients with severe congestive heart failure. Int. J. Cardiol. 85(2-3), 255-260 (2002).
125. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341(10), 709-717 (1999).
126. Quiros FR, Morillo CA, Casas JP, Cubillos LA, Silva FA. CHARITY: Chagas Cardiomyopathy Bisoprolol Intervention Study: a randomized double-blind placebo force-titration controlled study with bisoprolol in patients with chronic heart failure secondary to Chagas cardiomyopathy [NCT003239731. Trials 7, 21 (2006).
127. Rosa RF, Neto AS, Franken RA. Chagas' disease and the use of implantable cardioverter - defibrillators in Brazil. Am. J. Geriatr. Cardiol. 15(6), 372-376 (2006).
128. Bocchi EA, Fiorelli A. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. Ann. Thorac. Surg. 71(6), 1833-1838 (2001).
129. Fiorelli AI, Stolf NA, Honorato R et al. Later evolution after cardiac transplantation in Chagas' disease. Transplant. Proc. 37(6), 2793-2798 (2005).
130. Kawaguchi AT, Sugimachi M, Sunagawa K, Bergsland J, Koide S, Batista RJ. Improved left ventricular contraction and energetics in a patient with Chagas' disease undergoing partial left ventriculectomy. J. Card. Surg. 16(1), 30-33 (2001).
131. Claus M, Beling M, Grohmann A, Borges AC, Baumann G. Long-term results after partial left ventriculectomy. Int. J. Cardiol. 89 (2-3), 223-230 (2003).
132. Carvalho KA, Guarita-Souza LC, Hansen P et al. Cell transplantation after the coculture of skeletal myoblasts and mesenchymal stem cells in the regeneration of the myocardium scar: an experimental study in rats. Transplant. Proc. 38(5), 1596-1602 (2006).
133. Guarita-Souza LC, Carvalho KA, Woitowicz V et al. Simultaneous autologous transplantation of coculrured mesenchymal stem cells and skeletal myoblasts improves ventricular function in a murine model of Chagas disease. Circulation 114(1 Suppl.), I120-I124 (2006).
134. Soares MB, Lima RS, Rocha LL et al. Transplanted bone marrow cells repair heart tissue and reduce myocarditis in chronic chagasic mice. Am. J. Pathol. 164(2), 441-447 (2004).
135. Vilas-Boas F, Feitosa GS, Soares MB et al. Bone marrow cell transplantation to the myocardium of a patient with heart failure due to Chagas' disease. Arq. Bras. Cardiol. 82(2), 185-184 (2004).
136. Staudt A, Hummel A, Ruppert J et al. Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. Am. Heart J. 152(4), 712-716 (2006).
137. Labovsky V, Smulski CR, Gomez K, Levy G, Levin MJ. Anti-β1-adrenergic receptor autoantibodies in patients with chronic Chagas heart disease. Clin. Exp. Immunol. 148(3), 440-449 (2007).
138. Mendoza I, Guiniger A, Kushni E et al. [Consensus of the electrophysiology committee of "USCAS" on the treatment of ventricular arrhythmias in Chagas disease]. Arq. Bras. Cardiol. 62(1), 41-43 (1994).
139. Rassi JA, Gabriel RA, Gabriel RS, Rassi JL, Rassi A. [Ventricular arrhythmia in Chagas disease. Diagnostic, prognostic, and therapeutic features]. Arq. Bras. Cardiol. 65(4), 377-387 (1995).
140. Cardinalli-Neto A, Greco OT, Bestetti RB. Automatic implantable cardioverter-defibrillators in Chagas' heart disease patients with malignant ventricular arrhythmias. Pacing Clin. Electrophysiol. 29(5), 467-470 (2006).
141. Leite LR, Fenelon G, Paes AT, de Paola AA. The impact of syncope during clinical presentation of sustained ventricular tachycardia on total and cardiac mortality in patients with chronic chagasic heart disease. Arq. Bras. Cardiol. 77(5), 439-452 (2001).
142. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 344(8921), 493-498 (1994).
143. Singh SN, Fletcher RD, Fisher SG et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N. Engl. J. Med. 333(2), 77-82 (1995).
144. Rassi A Jr, Rassi A, Little WC. Chagas' heart disease. Clin. Cardiol. 23(12), 883-889 (2000).
145. d'Avila A, Splinter R, Svenson RH et al. New perspectives on catheter-based ablation of ventricular tachycardia complicating Chagas' disease: experimental evidence of the efficacy of near infrared lasers for catheter ablation of Chagas' VT. J. Interv. Card. Electrophysiol. 7(1), 23-38 (2002).
146. Gregoratos G, Abrams J, Epstein AE et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to update the 1998 pacemaker guidelines). Circulation 106(16), 2145-2161 (2002).
147. Sweeney MO, Hellkamp AS. Heart failure during cardiac pacing. Circulation 113(17), 2082-2088 (2006).
148. Nussenzveig I, Wajchemberg BL, Macruz R, Netto AS, Timoner J, do Serro Azul LG. [Embolic cerebral vascular accidents in chronic Chagas' heart disease.]. Arq. Neuropsiquiatr. 11(4), 386-402 (1953).
149. Schunemann HJ, Cook D, Grimshaw J et al. Antithrombotic and thrombolytic therapy: from evidence to application: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl.), 688S-696S (2004).
150. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl.), 204S-233S (2004).